Findings in this paper offer a plausible explanation for some of the mechanisms linking IGF-1 deficiency to the establishment of MetS and suggest this condition to be a novel candidate for IGF-1 replacement therapy. The gene discussed is IGF1; the disease is metabolic syndrome.